Abstract
Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.
| Original language | English |
|---|---|
| Pages (from-to) | 541-565 |
| Number of pages | 25 |
| Journal | Current Cancer Drug Targets |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jun 2009 |
Fingerprint
Keywords
- Gynecological cancer
- Immune response
- Immune signatures
- Prognostic indicators
- TAA
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology
- Cancer Research
Cite this
Immunology of gynecologic neoplasms : Analysis of the prognostic significance of the immune status. / Bellati, F.; Visconti, V.; Napoletano, C.; Antonilli, M.; Frati, L.; Panici, P. Benedetti; Nuti, M.
In: Current Cancer Drug Targets, Vol. 9, No. 4, 06.2009, p. 541-565.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunology of gynecologic neoplasms
T2 - Analysis of the prognostic significance of the immune status
AU - Bellati, F.
AU - Visconti, V.
AU - Napoletano, C.
AU - Antonilli, M.
AU - Frati, L.
AU - Panici, P. Benedetti
AU - Nuti, M.
PY - 2009/6
Y1 - 2009/6
N2 - Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.
AB - Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.
KW - Gynecological cancer
KW - Immune response
KW - Immune signatures
KW - Prognostic indicators
KW - TAA
UR - http://www.scopus.com/inward/record.url?scp=67649402262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649402262&partnerID=8YFLogxK
U2 - 10.2174/156800909788486722
DO - 10.2174/156800909788486722
M3 - Article
VL - 9
SP - 541
EP - 565
JO - Current Cancer Drug Targets
JF - Current Cancer Drug Targets
SN - 1568-0096
IS - 4
ER -